2015 年 41 巻 9 号 p. 612-623
Tazobactam/piperacillin (TAZ/PIPC) is a broad-spectrum antibiotic with anti-pseudomonal activity. Vancomycin (VCM) is primarily active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. These drugs are commonly used together as broad empirical therapy for hospitalized patients with Pseudomonas aeruginosa infections, catheter-associated infection and sepsis.
There have been several recent reports of increased nephrotoxicity associated with the concomitant use of VCM and TAZ/PIPC in adults. Our objective is to determine whether the addition of TAZ/PIPC leads to an increased incidence of nephrotoxicity in pediatric patients receiving VCM and to explore potential confounding factors of acute kidney injury (AKI).
We conducted a retrospective study to assess the incidence of AKI in pediatric patients treated with VCM alone, TAZ/PIPC alone or concomitant use (120 cases in each group). AKI was defined as an increase in serum creatinine (SCr) > 50% in serial creatinine measurements and indicates abnormal SCr level.
Fifteen (VCM), 6 (TAZ/PIPC) and 30 (concomitant use) patients met the criteria for AKI and the SCr increase rates were 38.2%, 34.8% and 61.7%. Long duration of therapy and high VCM trough levels were observed in patients with AKI. The incidence of VCM-related AKI was commonly associated with > 1% of fractional excretion rate of sodium, hyponatremia, hyperkalemia, metabolic acidosis and < 20 of blood urea nitrogen/SCr ratio, suggesting that AKI results from renal tubular injury.
We observed an increased incidence of AKI in pediatric patients with concomitant use of VCM and TAZ/PIPC, and require pharmaceutical management based on laboratory data.